

DAFTAR PUSTAKA

1. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. *The Lancet*. 395(10219), 200–211.
2. Nelwan EJ, Nelwan EJ. The Threat of Emerging and Re-emerging Infections in Indonesia. Vol. 51, *Acta Medica Indosiana*. 2019.
3. Mandell GL. *Mandell, Douglas, and Bennett's Principles and Practice of infectious diseases*. Churchill Livingstone/Elsevier; 2010.
4. Brooks GF. *Jawetz, Melnick & Adelberg's medical microbiology*. McGraw-Hill Medical; 2007. 818 p.
5. ReAct. ReAct Globally. 2022 [cited 2024 Jan 23]. 7.7 million people die from bacterial infections every year. Available from: <https://www.reactgroup.org/news-and-views/news-and-opinions/year-2022/7-7-million-people-die-from-bacterial-infections-every-year/>
6. Mustika GI, Kusbaryanto K. Literature Review The Implementation Of Infection Prevention And Control Programs On The Medical Staff. *JMMR (Jurnal Medicoeticolegal dan Manajemen Rumah Sakit)*. 2021;10(2):189–206.
7. Indonesia KR. *Profil Kesehatan Indonesia Tahun 2016*. Jakarta: KEMENKES RI.2017.
8. Rani GN, Budumuru R, Bandaru NR. Antimicrobial activity of honey with special reference to methicillin resistant staphylococcus aureus (MRSA) and methicillin sensitive staphylococcus aureus (MSSA). *Journal of Clinical and Diagnostic Research*. 2017;11(8):DC05–8.
9. WHO. World Health Organization. 2023 [cited 2024 Jan 23]. Antimicrobial resistance. Available from: <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>
10. Busroni. *Mediakom: Bahaya Bakteri yang Kebal Antibiotik*. Kemenkes RI. 2022;25.
11. Rossiter SE, Fletcher MH, Wuest WM. Natural Products as Platforms to Overcome Antibiotic Resistance. Vol. 117, *Chemical Reviews*. American Chemical Society; 2017. p. 12415–74.

12. Biswas B, Rogers K, McLaughlin F, Daniels D, Yadav A. Antimicrobial activities of leaf extracts of guava (*psidium guajava* L.) on two gram-negative and gram-positive bacteria. *Int J Microbiol.* 2013;2013(4).
13. Sine Y, Fallo G. Uji aktivitas antibakteri ekstrak daun ketapang (*Terminalia catappa* L.) dan daun jambu biji (*Psidium guajava* L.) terhadap pertumbuhan bakteri *Aeromonas hydrophila*. *Bio-Edu: Jurnal Pendidikan Biologi.* 2016;1(1):9–11.
14. Evans WC. *Trease and Evans' pharmacognosy.* Elsevier Health Sciences; 2009.
15. Zhou W, Wang Y, Lu A, Zhang G. Systems pharmacology in small molecular drug discovery. *International Journal of Molecular Sciences.* 2016; (2):246.
16. Aly SH, Eldahshan OA, Al-Rashood ST, Binjubair FA, El Hassab MA, Eldehna WM, et al. Chemical Constituents, Antioxidant, and Enzyme Inhibitory Activities Supported by In-Silico Study of n-Hexane Extract and Essential Oil of Guava Leaves. *Molecules.* 2022 Dec 16;27(24).
17. Porto WF, Irazazabal L, Alves ESF, Ribeiro SM, Matos CO, Pires AS, et al. In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design. *Nat Commun.* 2018 Dec 1;9(1).
18. Parra Coronado A. Maduración y comportamiento poscosecha de la guayaba (*Psidium guajava* L.). Una revisión. *Revista Colombiana de Ciencias Hortícolas.* 2015 Apr 16;8(2):314.
19. Gupta GK, Chahal J, Arora D. *Psidium guajava* Linn Current Research and Future Prospects. *J Pharm Res.* 2011;4(1):42–6.
20. Shabana S. Screening of Edible Plants for Urease Inhibitors and Chemical Structures of the Inhibitors [Internet]. 2009. Available from: <https://www.researchgate.net/publication/45596469>
21. Ugbogu EA, Emmanuel O, Ebubechi Uche M, Dike Dike E, Chukwuebuka Okoro B, Ibe C, et al. The ethnobotanical, phytochemistry and pharmacological activities of *Psidium guajava* L. *Arabian Journal of Chemistry.* 2022; 15 (5).
22. Naseer S, Hussain S, Naeem N, Pervaiz M, Rahman M. The phytochemistry and medicinal value of *Psidium guajava* (guava). *Clinical Phytoscience.* 2018 Dec;4(1).

23. Gutiérrez RMP, Mitchell S, Solis RV. Psidium guajava: A review of its traditional uses, phytochemistry and pharmacology. *Journal of Ethnopharmacology*. 2008; 117 (1): 1–27.
24. Sudrajat AC, Hardhani PR, Sukmawati AN, Arnov ST, Rimawati N. Effectiveness of Guava Leaf Extract (Syzygium Aqueum) in Inhibiting The Growth of Bacteria Aggregatibacter Actinomycetemcomitans. *South East Asia Nursing Research*. 2021;3(4).
25. Egra S, Rofin M, Adiwena M, Jannah N, Kuspradini H, Tohru Mitsunaga. Aktivitas Antimikroba Ekstrak Bakau (Rhizophora mucronata) dalam Menghambat Pertumbuhan Ralstonia Solanacearum Penyebab Penyakit Layu (Antimicrobial activity of Mangrove Extract (Rhizophora mucronata) inhibit Ralstonia solanacearum causes of Wilt). *Agrovigor*. 2019;12(1):26–31.
26. Lorena MC. *Influence of Guava Leaf Decoctions on Cholesterol Permeation through the Intestinal Barrier and Cholesterol Biosynthesis* Dissertação orientada por: Professora Doutora Maria Luísa Mourato Oliveira Marques Serralheiro Doutora Asma Ressaissi. [Campolide]: Universidade de Lisboa; 2020.
27. Kokilananthan S, Bulugahapitiya VP, Manawadu H, Gangabadage CS. Sesquiterpenes and monoterpenes from different varieties of guava leaf essential oils and their antioxidant potential. *Heliyon*. 2022 Dec 1;8(12).
28. Shirur, Shruthi D, Roshan A, Sharma Timilsina S, Sunita S. A Review on The Medicinal Plant Psidium Guajava Linn. (Myrtaceae). *Journal of Drug Delivery & Therapeutics*. 2011;2013(3):162–8.
29. Banu MSSK. Antimicrobial screening of leaf extract of Psidium guajava and its isolated fraction against some pathogenic microorganisms. *Drug Invent Today*. 2012 Mar;4(3):348–50.
30. Lahlou Y, Amraoui B El, El-Wahidi M, Bamhaoud T. Chemical Composition, Antioxidants and Antimicrobial Activities of Moroccan Species of Psidium Guajava Extracts. *Roczniki Panstwowego Zakladu Higieny*. 2022;73(1):65–77.
31. Madigan MT, Martinko JM, Brock TD. *Brock biology of microorganisms*. Pearson Prentice Hall; 2006. 34 p.
32. Fadrian. *Antibiotik, Infeksi dan Resistensi*. Padang: Andalas University Press; 2023.

33. Apweiler R. UniProt: the Universal Protein knowledgebase. *Nucleic Acids Res* [Internet]. 2004 Jan 1;32:115D – 119. Available from: <https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkh131>
34. Chang Y, Hawkins BA, Du JJ, Groundwater PW, Hibbs DE, Lai F. A Guide to In Silico Drug Design. *Pharmaceutics*. 2020; 15 (1): 49.
35. Colquitt RB, Colquhoun DA, Thiele RH. In silico modelling of physiologic systems. Vol. 25, Best Practice and Research: Clinical Anaesthesiology. *Bailliere Tindall Ltd*; 2011. p. 499–510.
36. Irawan AR, Mega Ramadhania Z, *Simulasi Molecular Docking dan Molecular Dynamics Senyawa Aktif Terhadap Neuraminidase Dari Influenza*. 2019.
37. Wadood A, Ahmed N, Shah L, Ahmad A, Hassan H, Shams S. Licensee OAPL (UK) 2013. Creative Commons Attribution License (CC-BY) In-silico drug design: An approach which revolutionarised the drug discovery process. *OA Drug Des Deliv*. 2013; 1(1):3.
38. Marrero-Ponce Y, Iyarreta-Veitía M, Montero-Torres A, Romero-Zaldivar C, Brandt CA, Ávila PE, et al. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps. *J Chem Inf Model*. 2005;45(4):1082–100.
39. Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery. *Pharmacological Reviews*. 2014; 66(1):334–95.
40. Dnyandev KM, Babasaheb GV, Chandrashekhar KV, Chandrakant MA, Vasant OK. A Review on Molecular Docking. *Int Res J Pure Appl Chem*. 2021; 22(3):60–8.
41. Pratama AA, Rifai Y, Marzuki A. Docking Molekuler Senyawa 5, 5'-Dibromometilsesamin. *Majalah Farmasi dan Farmakologi*. 2017;21(3):67-9.
42. Nurfadhila L, Muldianah D, Aprillia Nurdimayanthi D, Shafira Rahmawati D, Hartati H, Fadhilah H. Review Artikel: Pemanfaatan Kimia Komputasi Dengan Berbagai Metode Dalam Menentukan Desain Senyawa Baru. *Journal of pharmaceutical and Sciences*. 2023;6(2):555–66.
43. Hevener KE, Zhao W, Ball DM, Babaoglu K, Qi J, White SW, et al. Validation of molecular docking programs for virtual screening against dihydropteroate synthase. *J Chem Inf Model*. 2009;49(2):444–60.

44. Purnomo H. *Kimia komputasi: molecular docking plants penambatan molekul plants [protein-ligand-ant-system]*(“ilmu semut”). Yogyakarta: Pustaka Pelajar; 2013.
45. Iffah F, Fadillah F, Syuta AR, Purnama ER. *Molecular Docking*. Surabaya: FMIPA Unesa; 2022.
46. Putra PP. *Teori dan Tutorial Molecular Docking Menggunakan AutoDock Vina* . Edisi Pertama. Wahid N, editor. Banyumas: Wawasan Ilmu; 2022.
47. Feyza Maden S, Sezer S, Acuner SE. Fundamentals of Molecular Docking and Comparative Analysis of Protein-Small-Molecule Docking Approaches [Internet]. Erman Salih Istifli, editor. Rijeka: IntechOpen; 2023. Available from: <https://www.rcsb>.
48. Li J, Liu G, Zhen Z, Shen Z, Li S, Li H. Molecular Docking for Ligand-Receptor Binding Process Based on Heterogeneous Computing. *Scientific Programing*. 2022;2022 (1):9197606.
49. Huang SY, Zou X. Advances and challenges in Protein-ligand docking. *International Journal of Molecular Sciences*. 2010; 11(8): 3016–34.
50. Chen YZ, Zhi DG. Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule. *Proteins: Structure, Function, and Bioinformatics*. 2001;43(2):217–26.
51. Coleman RG, Carchia M, Sterling T, Irwin JJ, Shoichet BK. Ligand pose and orientational sampling in molecular docking. *PLoS One*. 2013;8(10):e75992.
52. Krumrine J, Raubacher F, Brooijmans N, Kuntz I. Principles and methods of docking and ligand design. *Structural bioinformatics*. 2003;44:441–76.
53. Du X, Li Y, Xia YL, Ai SM, Liang J, Sang P, et al. Insights into protein–ligand interactions: mechanisms, models, and methods. *Int J Mol Sci*. 2016;17(2):144.
54. Lipinski CA, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev*. 1997;23:3–25.
55. Fridlender M, Kapulnik Y, Koltai H. Plant derived substances with anti-cancer activity: from folklore to practice. *Front Plant Sci*. 2015;6:163161.

56. Harmita H, Harahap Y. *Kimia Medisinal*. Jakarta: EGC Halaman. 2011;53–5.
57. Grinter SZ, Zou X. Challenges, applications, and recent advances of protein-ligand docking in structure-based drug design. *Molecules*. 2014;19(7):10150–76.
58. Chen J, Almo SC, Wu Y. General principles of binding between cell surface receptors and multi-specific ligands: A computational study. *PLoS Comput Biol*. 2017;13(10):e1005805.
59. Guedes IA, de Magalhães CS, Dardenne LE. Receptor–ligand molecular docking. *Biophys Rev*. 2014;6:75–87.
60. Setiawati A, SB, Z, Suyatna F. *Pengantar Farmakologi. Farmakologi dan Terapi*. Edisi ke-4. Jakarta: Bagian Farmakologi UI; 2005. 14–19 p.
61. Chandrasekaran B, Abed SN, Al-Attraqchi O, Kuche K, Tekade RK. *Computer-Aided Prediction of Pharmacokinetic (ADMET) Properties*. In: Dosage Form Design Parameters. Elsevier; 2018. p. 731–55.
62. Lombardo F, Gifford E, Shalaeva MY. In Silico ADME Prediction: Data, Models, Facts and Myths. *Mini Rev Med Chem*. 2003;3(8):861–75.
63. Rydberg P, Gloriam DE, Zaretski J, Breneman C, Olsen L. SMARTCyp: A 2D method for prediction of cytochrome P450-mediated drug metabolism. *ACS Med Chem Lett*. 2010;1(3):96–100.
64. Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective. *Clinical Pharmacology and Therapeutics*;2015; 97 (3): 247–62.
65. Richard AM, William CR, Nascarella MA, Sipes NS, Birnbaum LS. Chemical Structure-based Methods for Predicting Environmental Toxicity. *Environ Health Perspect*. 2006;114(1):15–25.
66. Gjorgjieva M, Tomašič T, Barančokova M, Katsamakas S, Ilaš J, Tammela P, et al. Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors. *J Med Chem*. 2016;59(19):8941–54.
67. Heaslet H, Harris M, Fahnoe K, Sarver R, Putz H, Chang J, et al. Structural comparison of chromosomal and exogenous dihydrofolate reductase from *Staphylococcus aureus* in complex with the potent inhibitor trimethoprim. *Proteins: Structure, Function and Bioinformatics*. 2009;76(3):706–17.

68. Bernardo-García N, Mahasen K V., Batuecas MT, Lee M, Hesk D, Petráčková D, et al. Allosteric Recognition of Nascent Peptidoglycan, and Cross-linking of the Cell Wall by the Essential Penicillin-Binding Protein 2x of *Streptococcus pneumoniae*. *ACS Chem Biol*. 2018;13(3):694–702.
69. Nicholson D, Edwards TA, O’Neill AJ, Ranson NA. Structure of the 70S Ribosome from the Human Pathogen *Acinetobacter baumannii* in Complex with Clinically Relevant Antibiotics. *Structure*. 2020;28(10):1087-1100.
70. Hatami S, Sirous H, Mahnam K, Najafipour A, Fassihi A. Preparing a database of corrected protein structures important in cell signaling pathways. *Res Pharm Sci*. 2023;18(1):67–78.
71. Bassetti S, Tschudin-Sutter S, Egli A, Osthoff M. Optimizing antibiotic therapies to reduce the risk of bacterial resistance. *Eur J Intern Med*. 2022;99:7–12.
72. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. *J Med Chem*. 2006;49(21):6177–96.
73. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, et al. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. *J Med Chem*. 2004;47(7):1750–9.
74. Grassmann G, Di Rienzo L, Gosti G, Leonetti M, Ruocco G, Miotto M, et al. Electrostatic complementarity at the interface drives transient protein-protein interactions. *Sci Rep*. 2023 Dec 1;13(1).
75. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. *J Med Chem*. 2015;58(9):4066–72.
76. Jucker EM. *Progress in drug research*. Springer Science & Business Media; 2002.
77. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, et al. Central nervous system drug disposition: The relationship between in situ brain permeability and brain free fraction. *Journal of Pharmacology and Experimental Therapeutics*. 2007;322(1):205–13.
78. Honma M. An assessment of mutagenicity of chemical substances by (quantitative) structure-activity relationship. *Genes and Environment*. 2020; 42(1):23.

79. Babatola LJ, Oboh G. Extract of varieties of guava (*Psidium guajava* L.) leaf modulate angiotensin-1-converting enzyme gene expression in cyclosporine-induced hypertensive rats. *Phytomedicine Plus*. 2021;1(4).
80. Bhagavathy S, Mahendiran C, Kanchana R. Identification of glucosyl transferase inhibitors from *Psidium guajava* against *Streptococcus mutans* in dental caries. *J Tradit Complement Med*. 2019;9(2):124–37.
81. Nursanty R, Padzil KNBM, Ramli NIB, Mahyudin NA, Jaafar AH Bin, Rukayadi Y. Phytochemical analysis of ethanolic *Psidium guajava* leaves extract using GC-MS and LC-MS. *Biodiversitas*. 2023;24(5):2723–32.
82. Bezerra CF, Rocha JE, Nascimento Silva MK do, de Freitas TS, de Sousa AK, dos Santos ATL, et al. Analysis by UPLC-MS-QTOF and antifungal activity of guava (*Psidium guajava* L.). *Food and Chemical Toxicology*. 2018;119:122–32.
83. Flores G, Wu SB, Negrin A, Kennelly EJ. Chemical composition and antioxidant activity of seven cultivars of guava (*Psidium guajava*) fruits. *Food Chem*. 2015;170:327–35.
84. Chiari-Andréo BG, Trovatti E, Marto J, De Almeida-Cincotto MGJ, Melero A, Corrêa MA, et al. Guava: Phytochemical composition of a potential source of antioxidants for cosmetic and/or dermatological applications. *Brazilian Journal of Pharmaceutical Sciences*. 2017;53(2).
85. Fasola TR, Oloyede GK, Aponjolosun BS, Kehinde OLOYEDE G. Chemical Composition, Toxicity and Antioxidant Activities of Essential Oils of Stem Bark of Nigerian Species of Guava (*Psidium guajava* Linn.). *Excli Journal*. 2011;10:34–43.
86. Velmurugan S, Babu MM, Punitha MJ. Screening and characterization of antiviral compounds from *Psidium guajava* Linn. root bark against white spot syndrome virus. *Indian J Nat Prod Resour*. 2012;3(2):208–14.
87. Gutierrez-Montiel D, Guerrero-Barrera AL, Chávez-Vela NA, Avelar-Gonzalez FJ, Ornelas_Garcia IG. *Psidium guajava* L.: From byproduct and use in traditional Mexican medicine to antimicrobial agent. *Frontiers in Nutrition*. 2023;10:1108306.
88. Gutiérrez RMP, Mitchell S, Solis RV. *Psidium guajava*: A review of its traditional uses, phytochemistry and pharmacology. *Journal of Ethnopharmacology*. 2008; 117 (1): 1–27.